GABA receptor Inhibitors
3 drugsAbout GABA receptor
The GABA receptor is the primary inhibitory neurotransmitter receptor in the central nervous system (CNS), mediating the effects of gamma-aminobutyric acid (GABA) to decrease neuronal excitability. Its activation leads to reduced brain activity, playing a crucial role in neuronal signaling and maintaining brain homeostasis.
Human genetic studies provide strong validation for GABRA1 (max score 0.91) as a therapeutic target, with variants linked to developmental and epileptic encephalopathy, juvenile myoclonic epilepsy and childhood absence epilepsy. Loss-of-function variants are associated with increased disease risk, suggesting activation of GABA receptor may be beneficial.
GABA receptors are targeted by 3 FDA-approved small molecule drugs including FELBAMATE, ESZOPICLONE, and LUNESTA, primarily for CNS disorders. These drugs are marketed by ANI PHARMS, Sun Pharma and WAYLIS THERAP, spanning indications beyond the CNS.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
- phase3 represents biological uncertainty with 50% completion.
GABA receptor Genetic Evidence Strong
GABRA1 has strong genetic support (score 0.91) linking it to 13 diseases, including multiple forms of epilepsy.
Strong genetic support increases confidence in target validation and likelihood of clinical success.
💡 Why activation?
- • Loss-of-function variants increase disease risk (OR > 1) — restoring function may help
- • 100% directional consistency across 3 traits
- • Strong signal in nervous system disease, genetic, familial or congenital disease pathways
Cross-Disease Effects
Trade-off: LowDirection of Effect
100% alignedEvidence Across Diseases
13 totalGWAS and other genetic studies link GABRA1 to 13 diseases.
Loss-of-function causes disease; activation may help
Loss-of-function causes disease; activation may help
🔗 Colocalization Evidence 3 strong
max H4: 0.97eQTL/pQTL signals for GABRA1 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top GABA receptor Drugs
The GABA receptor market is concentrated among 3 companies: ANI PHARMS, Sun Pharma, and WAYLIS THERAP.
The limited number of players suggests potential for new entrants with differentiated GABA receptor modulators.
GABA receptor Drug Modality Landscape
Modalities
Routes of Administration
GABA receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like biologics could offer a competitive advantage in modulating GABA receptor activity.
GABA receptor Clinical Trials 27 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 5 | 1 | 1 | 83% |
| Phase 2 | 7 | 4 | 0 | 3 | 100% |
| Phase 3 | 6 | 5 | 0 | 1 | 100% |
| Phase 4 | 7 | 6 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
GABA receptor Drug Approval Timeline (2004 - 2012)
The first GABA receptor drug was approved in 2004 (LUNESTA), with the most recent approval in 2011 (ESZOPICLONE).
The relatively long gap since the last approval indicates a potential opportunity for innovative GABA receptor-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 30 clinical trials targeting GABA receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities